Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 8/2018

01-08-2018 | Original Article

Isolation and characterization of a group of new Proteus bacteriophages

Authors: V. Morozova, Yu. Kozlova, E. Shedko, I. Babkin, A. Kurilshikov, O. Bokovaya, A. Bardashova, A. Yunusova, A. Tikunov, A. Tupikin, T. Ushakova, E. Ryabchikova, N. Tikunova

Published in: Archives of Virology | Issue 8/2018

Login to get access

Abstract

Four lytic Proteus bacteriophages, PM75, PM85, PM93, and PM116, which are active against multi-drug-resistant strains of P. mirabilis, were isolated from cattle and poultry samples. According to electron microscopy data, all of the investigated phages belonged to the family Podoviridae. They all demonstrated lytic activity against sensitive strains of P. mirabilis, and three of the phages, PM85, PM93, and PM116, are potential candidates for use in antibacterial treatment. The genomes and putative proteins of bacteriophages PM85, PM93, and PM116 were similar to those of Proteus phage vB_PmiP_Pm5460 [KP890822], and the investigated phages formed a distinct clade within the genus Sp6virus, subfamily Autographivirinae. The genome sequence of phage PM75 was similar to that of a previously described Proteus phage, PM16 [KF319020], and both of them demonstrated low nucleotide sequence identity to the genomes of the other most similar phages, namely, Vibrio phage VP93, Pantoea phage LIMElight, and KP34-like bacteriophages. According to cluster analysis of the complete genome sequences and phylogenetic analysis of the proteins essential for their life cycle, phages PM75 and PM16 are distinct from other similar phages from the phiKMV supergroup and should be recognized as constituting a new genus, “Pm16virus”, within the subfamily Autographivirinae.
Appendix
Available only for authorised users
Literature
1.
2.
Adriaenssens E, Ceyssens P, Dunon V, Ackermann HW, Van Vaerenbergh J et al (2011) Bacteriophages LIMElight and LIMEzero of Pantoea agglomerans, belonging to the “phiKMV-like viruses”. Appl Environ Microbiol 77:3443–3450CrossRefPubMedPubMedCentral
3.
Bastías R, Higuera G, Sierralta W, Espejo RT (2010) A new group of cosmopolitan bacteriophages induce a carrier state in the pandemic strain of Vibrio parahaemolyticus. Environ Microbiol 12(4):990–1000CrossRefPubMed
4.
5.
Ceyssens P, Lavigne R, Mattheus W, Chibeu A, Hertveldt K et al (2006) Genome analysis of Pseudomonas aeruginosa phages LKD16 and LKA1: establishment of the phiKMV subgroup within the T7 supergroup. J Bacteriol 188:6924–6931CrossRefPubMedPubMedCentral
6.
Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, Shimono N, Akashi KJ (2013) Community spread of extended-spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: a long-term study in Japan. J Med Microbiol 62(Pt 7):1038–1043CrossRefPubMed
7.
Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A (2010) Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection 38(1):41–46CrossRefPubMed
8.
De Vecchi E, Sitia S, Romanò CL, Ricci C, Mattina R, Drago L (2013) Aetiology and antibiotic resistance patterns of urinary tract infections in the elderly: a 6-month study. J Med Microbiol 62(Pt 6):859–863CrossRefPubMed
9.
Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G et al (2005) Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 49(7):2598–2605CrossRefPubMedPubMedCentral
10.
Eriksson H, Maciejewska B, Latka A, Majkowska-Skrobek G, Hellstrand M, Melefors Ö, Wang J, Kropinski A, Drulis-Kawa Z, Nilsson A (2015) A suggested new bacteriophage genus, “Kp34likevirus”, within the Autographivirinae subfamily of Podoviridae. Viruses 7(4):1804–1822CrossRefPubMedPubMedCentral
11.
Esposito A, Gleckman R, Cram S, Crowley M, McCabe F, Drapkin M (1980) Community-acquired bacteremia in the elderly: analysis of one hundred consecutive episodes. J Am Geriatr Soc 28:315–319CrossRefPubMed
12.
13.
Frazer K, Pachter L, Poliakov A, Rubin E, Dubchak I (2004) VISTA: computational tools for comparative genomics. Nucleic Acids Res 32:W273–W279 (web server issue) CrossRefPubMedPubMedCentral
14.
Frickey T, Lupas AN (2004) CLANS: a Java application for visualizing protein families based on pairwise similarity. Bioinformatics 20:3702–3704CrossRefPubMed
15.
Grahnquist L, Lundberg B, Tullus K (1992) Neonatal Proteus meningoencephalitis. Case report. Acta Pathol Microbiol Immunol Scand 100:734–736CrossRef
16.
Hernández J, Martínez-Martínez L, Pascual A, Suárez A, Perea E (2000) Trends in the susceptibilities of Proteus mirabilis isolates to quinolones. J Antimicrob Chemother 45(3):407–408CrossRefPubMed
17.
18.
Jacobsen S, Stickler D, Mobley L, Shirtliff M (2008) Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 21(1):26–59CrossRefPubMedPubMedCentral
19.
Jacobsen S, Shirtliff M (2011) Proteus mirabilis biofilms and catheter-associated urinary tract infections. Virulence 2(5):460–465CrossRefPubMed
20.
21.
Kropinski AM (2009) Measurement of the rate of attachment of bacteriophage to cells. Methods Mol Biol 501:151–155CrossRefPubMed
22.
Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP (2009) Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol 501:69–76CrossRefPubMed
23.
Kumar S, Stecher G, Tamura K (2016) MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 33(7):1870–1874CrossRefPubMed
24.
Lu G, Moriyama E (2004) Vector NTI, a balanced all-in-one sequence analysis suite. Br Bioinform 5:378–388CrossRef
25.
Manos J, Belas R (2006) The genera Proteus, Providencia, and Morganella. In: Dworkin M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E (eds) Prokaryotes. Springer, Berlin, pp 245–260CrossRef
26.
Marx A, Hartshorne M, Stull M, Truwit C (1988) Case report 496: intraosseous gas in Proteus mirabilis osteomyelitis complicating bone infarcts in sickle cell disease. Skelet Radiol 17:510–513CrossRef
27.
28.
29.
Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B, Giusto M, Ceccarelli G, Farcomeni A, Riggio O, Venditti M (2015) The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS One 10(5):e0127448CrossRefPubMedPubMedCentral
30.
Morozova V, Kozlova Yu, Shedko E, Kurilshikov A, Babkin I, Tupikin A, Yunusova A, Chernonosov A, Baykov I, Kondratov I, Kabilov M, Ryabchikova E, Vlassov V, Tikunova N (2016) Lytic bacteriophage PM16 specific for Proteus mirabilis: a novel member of the genus phiKMVvirus. Arch Virol 161(9):2457–2472CrossRefPubMed
31.
Nzakizwanayo J, Hanin A, Alves D, McCutcheon B, Dedi C et al (2015) Bacteriophage can prevent encrustation and blockage of urinary catheters by Proteus mirabilis. Antimicrob Agents Chemother 60(3):1530–1536CrossRefPubMed
32.
O’Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald G, Ross R (2004) Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low GC content. J Bacteriol 186:2862–2871CrossRefPubMedPubMedCentral
33.
Pagava K, Metskhvarishvili G, Gachechiladze K, Korinteli I, Khoĭle N, Dzuliashvili M (2012) Some immunological changes in children with bacterial infections treated with bacteriophages. Georgian Med News 212:64–69
34.
Pajunen M, Kiljunen S, Skurnik M (2000) Bacteriophage phiYeO3-12, specific for Yersinia enterocolitica serotype O:3, is related to coliphages T3 and T7. J Bacteriol 182(18):5114–5120CrossRefPubMedPubMedCentral
35.
Parasion S, Kwiatek M, Gryko R, Mizak L, Malm A (2014) Bacteriophages as an alternative strategy for fighting biofilm development. Pol J Microbiol 63(2):137–145PubMed
36.
Pearson M, Sebaihia M, Churcher C, Quail MA, Seshasayee A et al (2008) Complete genome sequence of uropathogenic Proteus mirabilis, a master of both adherence and motility. J Bacteriol 190:4027–4037CrossRefPubMedPubMedCentral
37.
Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406–425PubMed
38.
Semina NA, Sidorenko SV, Rezvan SP (2004) Guidelines for antibiotic susceptibility testing no 4.2.1890-04. Clin Microbiol Antimicrob Chemother 6(4):306–359
39.
Siebor E, Neuwirth C (2013) Emergence of Salmonella genomic island 1 (SGI1) among Proteus mirabilis clinical isolates in Dijon, France. J Antimicrob Chemother 68(8):1750–1756CrossRefPubMed
40.
Scholl D, Kieleczawa J, Kemp P, Rush J, Richardson C et al (2004) Genomic analysis of bacteriophages SP6 and K1-5, an estranged subgroup of the T7 supergroup. J Mol Biol 335:1151–1171CrossRefPubMed
41.
42.
Tumbarello M, Trecarichi E, Fiori B, Losito A, D’Inzeo T et al (2012) Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother 56(6):3224–3231CrossRefPubMedPubMedCentral
43.
Vakarina A, Kataeva L, Karpukhina N (2015) Rational aspects of bacteriophages use. Zh Mikrobiol Epidemiol Immunobiol 5:76–79
44.
45.
Watanakunakorn C, Perni S (1994) Proteus mirabilis bacteremia: a review of 176 cases during 1980–1992. Scand J Infect Dis 26(4):361–367CrossRefPubMed
46.
Witoszka M, Strumillo B (1963) Attempted treatment of infected wounds with bacteriophage. Pol Przegl Chir 35:1054–1056PubMed
47.
Yamamoto KR, Alberts BM, Benzinger R, Lawhorne L, Treiber G (1970) Rapid bacteriophage sedimentation in the presence of polyethylene glycol and its application to large-scale virus purification. Virology 40(3):734–744CrossRefPubMed
48.
Yoshikawa T, Shibata S, Chow A, Guze L (1978) Outbreak of multiply drug-resistant Proteus mirabilis originating in a surgical intensive care unit: in vitro susceptibility pattern. Antimicrob Agents Chemother 13(2):177–179CrossRefPubMedPubMedCentral
Metadata
Title
Isolation and characterization of a group of new Proteus bacteriophages
Authors
V. Morozova
Yu. Kozlova
E. Shedko
I. Babkin
A. Kurilshikov
O. Bokovaya
A. Bardashova
A. Yunusova
A. Tikunov
A. Tupikin
T. Ushakova
E. Ryabchikova
N. Tikunova
Publication date
01-08-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 8/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-3853-3

Other articles of this Issue 8/2018

Archives of Virology 8/2018 Go to the issue

Original Article

Host serum microRNA profiling during the early stage of foot-and-mouth disease virus infection

In honor of Marc van Regenmortel

Virus classification – where do you draw the line?

Original Article

Bursal immunopathology responses of specific-pathogen-free chickens and red jungle fowl infected with very virulent infectious bursal disease virus

In honor of Marc van Regenmortel - Editorial

Editorial

Original Article

Surveillance of HIV-1 drug resistance in Xinjiang: high prevalence of K103N in treatment-naïve individuals

Annotated Sequence Record

Complete genome sequence of peanut virus C, a putative novel ilarvirus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits